News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Interleukin Genetics Inc. (ILGN) and Renaissance Health Service Corporation Enter Into a Preferred Participation Agreement for PST® Genetic Test


3/5/2013 9:52:26 AM

WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB: ILIU), which is pioneering the use of genetic information for the prevention and improved management of certain chronic conditions of aging, today announced that it has entered into a three year Preferred Participation Agreement with Renaissance Health Service Corporation, and certain of its affiliates and subsidiaries, (collectively “RHSC”). Pursuant to the Agreement, RHSC has agreed to reimburse Interleukin a fixed price for each PST® genetic test that it processes for a customer of RHSC. Interleukin’s proprietary PST® genetic risk panel for periodontal disease severity and tooth loss susceptibility addresses the need to identify individuals who are at greater risk of severe periodontitis, a primary cause of tooth loss.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES